Certara announced that it has released D360™ version 9.0 along with D360 Express, its data informatics platform for discovery scientists. D360 is a self-service data access, integration and visualization solution used to query multiple cheminformatics and bioinformatics data sources and make informed go/no-go and next step research decisions. Certara’s D360 is the scientific informatics platform for integrating and leveraging the large amounts of diverse scientific data generated in discovery research. D360 enables scientists to cut dramatically the time required to provision data. They estimate that this change allows them to increase by more than 50% the time they spend performing pivotal scientific modeling and analysis, advancing compounds, and making informed decisions. D360 version 9 and D360 Express offer several new features, including the following: Virtual Compound Capabilities – D360 now provides full support for virtual compounds – chemical structures not available in source systems. Compounds can be added to datasets from external sources or from a sketch. New chemical structure ideas can be shared, assessed and prioritized alongside known test entities. Complex Assay Data Handling – Data query capabilities have been extended scientifically to handle more complex assays to be evaluated for new research initiatives including precision medicine. Enhanced Performance – D360’s strength is that it allows scientists to access their data quickly and easily and to move swiftly to action. Certara has improved all aspects of D360 performance, including data queries, data formatting and analysis, response to ad hoc questions, and handling of large and/or complex datasets. Faster data retrieval and enhanced query features allow scientists to more readily mine corporate data for scientific insight rather than relying on specific data feeds.
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development in the global biopharmaceutical industry. It is focused on producing medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its customers include life sciences companies of all sizes along with contract research organizations, academic institutions, and global regulators. Its software and service are used by approximately 2,400 biopharmaceutical companies and academic institutions across 66 countries, including 38 of the top 40 biopharmaceutical companies. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, Netherlands, Philippines, Poland, Portugal, Spain, Switzerland, Egypt, and the United Kingdom.